Plus   Neg

Bristol-Myers Wins $752 Mln In US Patent Case Against Gilead Sciences

Bristol-Myers Squibb Co (BMY) announced that it has won jury verdict against Gilead Sciences Inc (GILD) in a U.S. patent dispute relating to technology for treating cancer.

A jury in Los Angeles ordered Gilead's Kite Pharma to pay $752 million to Bristol-Myers Squibb' Juno Therapeutics division, which sued in 2017 for patent infringement.

In its lawsuit, Juno alleged Kite scientific collaborators copied research by scientists at Sloan Kettering to advance Kite's CAR-T work and eventually win approval for Yescarta.

"We remain steadfast in our opinion that Sloan Kettering's patent is not infringed and is invalid," Gilead said in a statement. "Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages."

A BMS spokesperson said the company is pleased with the decision and Gilead said it expected to seek to undo the verdict through post-trial motions and a potential appeal.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT